How is the diagnosis of immunoglobulin A (IgA) nephropathy made?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

How is the Diagnosis of IgA Nephropathy Made?

IgA nephropathy can only be diagnosed with a kidney biopsy showing mesangial dominant or co-dominant IgA deposition on immunofluorescence microscopy 1, 2.

Diagnostic Algorithm

When to Suspect IgA Nephropathy

Look for these specific clinical presentations:

  • Microscopic hematuria with proteinuria (detected incidentally in ~60% of cases) 3
  • Episodic visible hematuria occurring during or immediately after upper respiratory or gastrointestinal infections (synpharyngitic hematuria) in up to 30% of patients 3
  • Nephrotic syndrome (<5% of cases) 3
  • Rapidly progressive glomerulonephritis (<5% of cases) 3

Indications for Kidney Biopsy

Perform kidney biopsy in all adults with suspected IgA nephropathy who have proteinuria ≥0.5 g/day 2, 3. The 2025 KDIGO guideline encourages a more liberal biopsy policy to ensure early diagnosis and prompt treatment 2.

For patients with preserved eGFR and proteinuria <500 mg/g with low suspicion for other glomerular disorders, a patient-centered discussion about biopsy utility is reasonable, with alternatives including watchful waiting and serial monitoring 1.

Required Biopsy Studies

The diagnosis requires three complementary microscopy techniques:

1. Immunofluorescence (Mandatory)

  • Must demonstrate mesangial dominant or co-dominant IgA staining (2+ or greater intensity) 4
  • IgA staining should be present in the mesangium, either segmentally or globally 4
  • Pattern is typically granular 4
  • C3 complement is often present; C1q is characteristically absent or scanty (<2+), which helps differentiate from lupus nephritis 4, 5

2. Light Microscopy

  • Determine the MEST-C score according to the revised Oxford Classification 1, 2:
    • M = Mesangial hypercellularity
    • E = Endocapillary hypercellularity
    • S = Segmental sclerosis
    • T = Interstitial fibrosis/tubular atrophy
    • C = Crescents
  • This scoring provides prognostic information independent of clinical characteristics 1

3. Electron Microscopy

  • Confirms mesangial electron-dense deposits 4
  • Helps exclude other glomerular diseases with similar presentations 4

Critical Diagnostic Pitfall

There are no validated diagnostic serum or urine biomarkers for IgA nephropathy 1, 2. While elevated serum IgA levels and serum IgA/C3 ratios may support clinical suspicion, they cannot establish the diagnosis 6. The kidney biopsy remains mandatory.

Exclude Secondary Causes

After confirming IgA-dominant mesangial deposits, assess all patients for secondary causes 1:

  • IgA vasculitis (Henoch-Schönlein purpura)
  • IgA-dominant infection-related glomerulonephritis
  • Cirrhosis
  • Inflammatory bowel disease
  • Celiac disease
  • Chronic infections (viral hepatitis)
  • Autoimmune diseases (axial spondyloarthritis) 3

The diagnosis of primary IgA nephropathy is made only after excluding these secondary causes 3.

Distinguishing Features on Immunofluorescence

IgA nephropathy has distinctive immunohistologic characteristics 5:

  • High frequency (67%) of greater lambda than kappa light chain staining
  • Absent or scanty C1q staining (helps differentiate from lupus nephritis, which shows prominent C1q)
  • When using criteria of ≥2+ dominant/co-dominant mesangial IgA with <2+ C1q, diagnostic accuracy reaches 98% 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.